2. UroToday Home
  3. Recent Abstracts
  4. Urologic Oncology
  5. Bladder Cancer

Development and Analytical Validation of a Multiplex Diagnostic qPCR-Array as a Potential Application in Predicting the Response to Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer - Beyond the Abstract

Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy remains the standard of care for muscle-invasive bladder cancer (MIBC). Yet, only a subset of patients derive meaningful benefit, while many are exposed to toxicity and surgical delays without improved outcomes. The field has long sought predictive biomarkers to better select candidates for NAC, but reproducibility and clinical practicality have hindered adoption.

In a recent study published in Translational Oncology, Drs. Sakatani, Rosser, Furuya, and colleagues report the analytical validation of a multiplex qPCR-array designed to quantify a 10-gene bladder cancer–associated signature. The array demonstrated strong technical performance across formalin-fixed paraffin-embedded (FFPE) and fresh-frozen tissues, robustness to pre-analytical variation (RNA input, storage conditions, necrosis), and reproducibility across operators. Importantly, the assay was developed with a clinical laboratory workflow in mind, meeting CLSI standards for analytical validation.

What distinguishes this work is its focus on clinical feasibility. Unlike broad sequencing panels, the qPCR-array offers a cost-effective, scalable, and rapid assay that can be applied to standard biopsy or surgical specimens. If prospectively validated, this approach could enable clinicians to stratify MIBC patients before definitive surgery—directing likely responders to NAC while sparing non-responders from unnecessary toxicity.

We are currently pursuing clinical validation of this assay, and we hope to share those results with the community soon. Together, these steps may bring us closer to a practical, reproducible tool for guiding chemotherapy decisions in MIBC.

Written by: Hideki Furuya, Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA

Read the Abstract